ARS Pharmaceuticals (SPRY) Payables: 2021-2025
Historic Payables for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $49.8 million.
- ARS Pharmaceuticals' Payables rose 201.24% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.9 million, marking a year-over-year increase of 400.67%. This contributed to the annual value of $22.8 million for FY2024, which is 960.40% up from last year.
- As of Q3 2025, ARS Pharmaceuticals' Payables stood at $49.8 million, which was up 12.43% from $44.3 million recorded in Q2 2025.
- ARS Pharmaceuticals' Payables' 5-year high stood at $49.8 million during Q3 2025, with a 5-year trough of $126,000 in Q3 2022.
- Its 3-year average for Payables is $18.5 million, with a median of $10.9 million in 2023.
- Per our database at Business Quant, ARS Pharmaceuticals' Payables tumbled by 92.67% in 2022 and then surged by 8,586.51% in 2023.
- ARS Pharmaceuticals' Payables (Quarterly) stood at $6.6 million in 2021, then decreased by 25.13% to $4.9 million in 2022, then tumbled by 56.32% to $2.2 million in 2023, then spiked by 960.40% to $22.8 million in 2024, then surged by 201.24% to $49.8 million in 2025.
- Its Payables was $49.8 million in Q3 2025, compared to $44.3 million in Q2 2025 and $27.0 million in Q1 2025.